home / stock / adxs / adxs quote
Last: | $0.24 |
---|---|
Change Percent: | -18.45% |
Open: | $0.29 |
Close: | $0.24 |
High: | $0.2902 |
Low: | $0.2356 |
Volume: | 11,640,473 |
Last Trade Date Time: | 12/22/2021 04:55:26 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.24 | $0.29 | $0.24 | $0.2902 | $0.2356 | 11,640,473 | 12-22-2021 |
$0.2943 | $0.3033 | $0.2943 | $0.3033 | $0.287 | 3,165,617 | 12-21-2021 |
$0.2962 | $0.32 | $0.2962 | $0.32 | $0.2746 | 3,752,751 | 12-20-2021 |
$0.325 | $0.3204 | $0.325 | $0.328 | $0.305 | 2,379,154 | 12-17-2021 |
$0.31 | $0.32 | $0.31 | $0.33 | $0.3033 | 1,453,107 | 12-16-2021 |
$0.3174 | $0.3 | $0.3174 | $0.3245 | $0.293 | 1,714,019 | 12-15-2021 |
$0.309 | $0.3126 | $0.309 | $0.3299 | $0.3 | 2,765,718 | 12-14-2021 |
$0.3126 | $0.3159 | $0.3126 | $0.33 | $0.3045 | 1,798,014 | 12-13-2021 |
$0.325 | $0.3718 | $0.325 | $0.377 | $0.32 | 3,015,216 | 12-10-2021 |
$0.3478 | $0.3692 | $0.3478 | $0.382 | $0.347 | 2,360,508 | 12-09-2021 |
$0.36 | $0.343 | $0.36 | $0.366 | $0.3398 | 1,672,367 | 12-08-2021 |
$0.3544 | $0.3538 | $0.3544 | $0.3799 | $0.35 | 2,844,696 | 12-07-2021 |
$0.3445 | $0.3134 | $0.3445 | $0.348 | $0.3013 | 2,738,762 | 12-06-2021 |
$0.311 | $0.3442 | $0.311 | $0.3476 | $0.3102 | 2,833,219 | 12-03-2021 |
$0.3442 | $0.3408 | $0.3442 | $0.353 | $0.3377 | 1,848,516 | 12-02-2021 |
$0.3444 | $0.37 | $0.3444 | $0.3725 | $0.3302 | 3,256,281 | 12-01-2021 |
$0.37 | $0.4 | $0.37 | $0.41 | $0.365 | 3,299,557 | 11-30-2021 |
$0.4002 | $0.3902 | $0.4002 | $0.42 | $0.3622 | 8,359,562 | 11-29-2021 |
$0.3847 | $0.3763 | $0.3847 | $0.3897 | $0.365 | 1,656,652 | 11-26-2021 |
$0.4017 | $0.3665 | $0.4017 | $0.4199 | $0.36 | 5,562,544 | 11-25-2021 |
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...